Pfenex Inc. - Investors http://pfenex.investorroom.com/ Pfenex and NT Pharma Enter into a Development and License Agreement for Pfenex's PF708 Therapeutic Equivalent Candidate to Forteo® http://pfenex.investorroom.com/2018-04-18-Pfenex-and-NT-Pharma-Enter-into-a-Development-and-License-Agreement-for-Pfenexs-PF708-Therapeutic-Equivalent-Candidate-to-Forteo-R Wed, 18 Apr 2018 17:00:00 -0400 http://pfenex.investorroom.com/2018-04-18-Pfenex-and-NT-Pharma-Enter-into-a-Development-and-License-Agreement-for-Pfenexs-PF708-Therapeutic-Equivalent-Candidate-to-Forteo-R Pfenex Reports Fourth Quarter and Full Year 2017 Results and Provides Business Update http://pfenex.investorroom.com/2018-03-15-Pfenex-Reports-Fourth-Quarter-and-Full-Year-2017-Results-and-Provides-Business-Update Thu, 15 Mar 2018 16:02:00 -0400 http://pfenex.investorroom.com/2018-03-15-Pfenex-Reports-Fourth-Quarter-and-Full-Year-2017-Results-and-Provides-Business-Update Pfenex Inc. to Present at Oppenheimer's 28th Annual Healthcare Conference http://pfenex.investorroom.com/2018-03-13-Pfenex-Inc-to-Present-at-Oppenheimers-28th-Annual-Healthcare-Conference Tue, 13 Mar 2018 16:15:00 -0400 http://pfenex.investorroom.com/2018-03-13-Pfenex-Inc-to-Present-at-Oppenheimers-28th-Annual-Healthcare-Conference Pfenex to Report Fourth Quarter and Full Year 2017 Results and Provide Business Update on Thursday, March 15, 2018 http://pfenex.investorroom.com/2018-03-08-Pfenex-to-Report-Fourth-Quarter-and-Full-Year-2017-Results-and-Provide-Business-Update-on-Thursday-March-15-2018 Thu, 08 Mar 2018 16:15:00 -0500 http://pfenex.investorroom.com/2018-03-08-Pfenex-to-Report-Fourth-Quarter-and-Full-Year-2017-Results-and-Provide-Business-Update-on-Thursday-March-15-2018 Pfenex Inc. to Present at Barclay's 2018 Global Healthcare Conference http://pfenex.investorroom.com/2018-02-27-Pfenex-Inc-to-Present-at-Barclays-2018-Global-Healthcare-Conference Tue, 27 Feb 2018 16:15:00 -0500 http://pfenex.investorroom.com/2018-02-27-Pfenex-Inc-to-Present-at-Barclays-2018-Global-Healthcare-Conference